Literature DB >> 11563686

Flutamide-induced acute hepatitis in advanced prostate cancer patients.

I Kraus1, D Vitezic, R Oguic.   

Abstract

OBJECTIVE: To describe the characteristics of 3 patients hospitalized in the Department of Gastroenterology, University Hospital Center, Rijeka, as the result of acute hepatitis, a rare adverse drug reaction to flutamide. PATIENTS AND
RESULTS: All 3 patients with advanced prostate carcinoma were treated with oral flutamide at a dose rate of 250 mg 3 times daily. The patients developed clinical signs (jaundice, anorexia, nausea, dark urine etc.) and laboratory liver function test changes (high aminotransferase and bilirubin level), indicative of acute hepatitis, 20-22 weeks after commencing flutamide treatment. The flutamide therapy was immediately discontinued and this resulted in spontaneous remission (clinical and liver function test results returned to normal) during the next 8 weeks.
CONCLUSION: Our data clearly suggest that flutamide causes acute hepatitis and that the monitoring of the patients' liver function tests in order to detect these changes as early as possible, is important.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11563686     DOI: 10.5414/cpp39395

Source DB:  PubMed          Journal:  Int J Clin Pharmacol Ther        ISSN: 0946-1965            Impact factor:   1.366


  2 in total

Review 1.  [Toxic hepatitis and liver failure under therapy with flutamide].

Authors:  C Lübbert; M Wiese; R Haupt; B R Ruf
Journal:  Internist (Berl)       Date:  2004-03       Impact factor: 0.743

2.  Comparison of in vitro bioactivation of flutamide and its cyano analogue: evidence for reductive activation by human NADPH:cytochrome P450 reductase.

Authors:  Bo Wen; Kevin J Coe; Peter Rademacher; William L Fitch; Mario Monshouwer; Sidney D Nelson
Journal:  Chem Res Toxicol       Date:  2008-12       Impact factor: 3.739

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.